Northway Biotech
24.5.2023 18:24:40 CEST | ACCESS Newswire | Press release
WALTHAM, MA / ACCESSWIRE / May 24, 2023 / Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), established in 2004, with an EMA and FDA-compliant, state-of-the-art cGMP manufacturing site in Vilnius, Lithuania, announced the completion of its expansion project for cGMP manufacturing facilities in Waltham, Massachusetts. This significant accomplishment further solidifies Northway Biotech's standing as an influential player in the global biopharmaceutical landscape.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.This recent growth is an extension of the successful launch of Northway Biotech's process and analytical development laboratories in Waltham (Greater Boston area) in 2020. The expanded facility now includes state-of-the-art cGMP suites, marking a significant milestone in the company's journey. The newly established cutting-edge biomanufacturing suites host a microbial fermentation train with up to 450 liters of volume capacity, and a mammalian production train with the ability to handle volumes of up to 2,000 liters. Northway Biotech has further established a specialized, fully automated fill and finish line to accommodate its clients' varied needs, supporting high-throughput filling into vials, syringes, and cartridges.
Prof. Vladas Algirdas Bumelis, CEO of Northway Biotech, shared his insights regarding this accomplishment, stating, "The addition of GMP suites in our US site represents a transformative step for our organization, enabling us to provide comprehensive end-to-end solutions from our second site now. We are poised to transition current process development projects into the cGMP manufacturing phase in a timely manner, in line with our clients' committed schedules. Additionally, our longstanding US partners who have engaged with our Lithuanian site can now also take advantage of the geographical convenience of our modern facilities located in the Greater Boston Area. With our fully functional and technologically advanced manufacturing site at our disposal, Northway Biotech is perfectly positioned to take on manufacturing projects aimed at both clinical and commercial supply."
To commemorate this significant expansion and express gratitude to its valued partners and industry leaders, Northway Biotech will be hosting a grand opening event for its cGMP suites on June 8. This event promises to be an occasion of celebration and networking, providing an opportunity for attendees to witness firsthand the state-of-the-art facilities and engage in meaningful discussions within the biotech community.
About Northway Biotech - https://www.northwaybiotech.com
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately-owned company founded in 2004 and located in Vilnius, Lithuania; London, United Kingdom; and Waltham, Massachusetts, United States.
For Further Information, Contact:
Prof. Vladas Algirdas Bumelis
CEO and Chairman of the Board
Northway Biotech
vladas.bumelis@northwaybiotech.com
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/757061/Northway-Biotech-Set-to-Launch-Advanced-Microbial-and-Mammalian-GMP-Facilities-in-Massachusetts
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
ePropelled to Showcase Next Generation Electric Propulsion, Software Innovation and Autonomous Systems Capabilities at Farnborough International Airshow 202617.7.2026 17:00:00 CEST | Press release
Meet the ePropelled team in Hall 2, Stand 2039, on the New Hampshire Mission Pavilion FARNBOROUGH, UK / ACCESS Newswire / July 17, 2026 / ePropelled, a leading global provider of smart propulsion solutions and energy management systems, will exhibit at the Farnborough International Airshow 2026, showcasing its latest innovations for aerospace, defense and uncrewed vehicle applications. Visitors to Hall 2, Stand 2039 on the New Hampshire Mission Pavilion will have the opportunity to meet the ePropelled team and learn about a range of exciting developments, including new product launches, software innovations, technology updates and exclusive previews of next-generation solutions currently in development. With autonomy, electrification and intelligent mobility driving the future of aerospace and defence, ePropelled continues to develop advanced propulsion, power management and software technologies that enhance performance, efficiency and mission capability across air, land and maritime
As the UK Backs Life Sciences and Advanced Manufacturing, US PMO Firm MustardSeed Moves In to Help Deliver It16.7.2026 11:00:00 CEST | Press release
The expansion reflects growing client demand for embedded programme management support across highly regulated industries. WEST CHESTER, PA AND MANCHESTER, UK / ACCESS Newswire / July 16, 2026 / The UK Government's 2025 Modern Industrial Strategy has put life sciences, advanced manufacturing, defence, and clean energy at the centre of Britain's growth agenda. MustardSeed, a US-based programme management and PMO consultancy, is launching UK operations to help organisations in those sectors deliver on that ambition. The 2025 Modern Industrial Strategy names life sciences and advanced manufacturing among its eight priority sectors, alongside defence and clean energy. These are industries defined by complex, regulated, multi-stakeholder programmes where disciplined execution directly determines commercial and operational outcomes. MustardSeed, headquartered in West Chester, Pennsylvania, has built its practice around delivering that execution. The firm announced today the launch of its UK
Akkodis Recognized in the 2026 Gartner(R) Emerging Market Quadrant for Physical AI Services16.7.2026 06:45:00 CEST | Press release
Akkodis continues to advance full-stack engineering expertise and industrial-grade AI deployments. ZURICH, SWITZERLAND / ACCESS Newswire / July 16, 2026 / Akkodis, a global digital engineering consulting company and part of the Adecco Group, has been recognized as a Specialist in the Gartner Emerging Market Quadrant for Physical AI Services (PAIS), published on June 8, 2026. Physical AI services address the complex challenge of designing, developing, deploying and operating AI‑enabled physical systems - such as robots, autonomous systems including, vehicles, drones and industrial infrastructure - in real‑world environments. The Gartner report states "The PAIS market is moving from exploratory experimentation toward operational reliability at scale. This trend is driven by mounting labor constraints, safety requirements, infrastructure modernization and advances in AI, simulation and automation technologies." Full‑stack Physical AI capabilities with real‑world impact and measurable outc
Loar Holdings Inc. Announces Date and Time for Second Quarter 2026 Earnings and Conference Call15.7.2026 22:15:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / July 15, 2026 / Loar Holdings Inc. (NYSE:LOAR) will report Q2 2026 earnings before the market opens on Thursday, August 6, 2026. A conference call will follow at 11:00a.m. Eastern Time. To participate in the call telephonically please dial +1 877-407-0670 / +1 215-268-9902. International participants can find a list of toll-free numbers here. A live audio webcast will also be available at the following link as well as through the Investor section of Loar Holdings website: https://ir.loargroup.com The webcast will be archived and available for replay later in the day. About Loar Holdings Inc. Loar Holdings Inc. is a diversified manufacturer and supplier of niche aerospace and defense components that are essential for today's aircraft and defense systems. Loar has established relationships across leading aerospace and defense original equipment manufacturers and Tier Ones worldwide. Contact Ian McKillop Loar Holdings Inc. Investor Relations IR@loargro
Fermi Outlines Strategic Rationale for Upsized $431 Million Convertible Notes Offering15.7.2026 14:30:00 CEST | Press release
Flexible convertible structure with shareholder-friendly capped call minimizes dilution Proceeds strengthen liquidity in midst of customer and partner negotiations and preserve Fermi's speed-to-power advantage Attractive five-year cost of capital provides run room to advance multiple commercial tracks in parallel DALLAS, TX / ACCESS Newswire / July 15, 2026 / Fermi Inc. (Nasdaq:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), outlined today the strategic rationale for its recently closed and upsized offering of $431.25 million aggregate principal amount of 5.00% Convertible Senior Notes due 2031 (the "Notes"), which included the exercise in full of the initial purchasers' 13-day option to purchase up to an additional $56.25 million aggregate principal amount of Notes. The Notes are intended to strengthen Fermi's balance sheet, enhance liquidity, and support continued execution of Project Matador as the Company advances tenant, strategic partnership, and power-de
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom